Interdisciplinary model-informed drug development for extending duration of elagolix treatment in patients with uterine fibroids.

The elagolix integrated exposure-BMD analysis and translation to fracture risk provided an interdisciplinary model-informed drug development framework for clinical benefit-risk evaluation and enabled approval of longer treatment duration to benefit the patient.